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which was found to be specific. 
That these experimental studies have 
some bearing on the clinical problem was 
demonstrated by Schwarzenberg and 
Mathe (Villejuif, France). They showed 
that allogeneic bone marrow transferred 
to whole body irradiated patients suffer-
ing from acute leukcemia produced com-
plete remission in four patients. Transfer 
of white blood cells resulted in remission 
in 10/21 patients with acute leukcemia. 
Regression of pleural and ascitic fluid was 
obtained after the local injection of 
heterologous lymphocytes immunised 
against the tumour. 
Although it is too early to be op-
timistic about these new lines of treat-
ment, it can be seen that an immunological 
attack against cancer is possible, and some 
progress has been made in recognising 
antigenic sites on the tumour which are 
lacking in the host; in the preparation of 
lymphoid cells or fractions thereof (e.g. 
RNA) that are capable of attacking the 
tumour cells and thus help the host to 
reject the tumour; and finally, in the use 
of graft-versus-host reaction employing 
allogeneic lymphoid cells to enhance re-
jection of tumour. These and similar me-
thods can be useful adjuncts to radio- or 
chemo-therapy. 
G. Conclusion 
The rapid rate of expansion in the 
field of transplantation witnessed in the 
last few years can be confidently expected 
to continue. New techniques of organ 
transplantation, new concepts in the anti-
genic structure of cells, new methods of 
purifying subcellular fraction of anti-
lymphocytic serum, new drugs to combat 
rejection phenomena, and above all a 
fresh outlook on the mode of action of 
these drugs at a molecular level, will 
doubtless render this an exciting new ap-
proach to biology in general and to clinical 
problems in particular. 
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Coagulation defects are only rarely 
met with in obstetrics. It is probable that 
the complication is nowadays oemg 
diagnosed with increasing frequency, 
owing mainly to a greater awareness of 
the condition. In Mulago Hospital where 
the author practises, it occurred 11 times 
in about 33,500 deliveries in the period 
1964-66. This gives an incidence of about 
0.03%. In cases of concealed accidental 
hcemorrhage the incidence is however 
higher; it appears to occur in some 5% 
of cases. 
Historical background 
The first reported case dates back to 
1901 when De Lee (1901) described death 
in a patient from post partum hcemorrhage 
as being clue to a "Hcemophilia-like phe-
nomenon" which followed concealed acci-
dental hcemorrhage. In 1936 Dieckmann 
(1936) was the first to suggest that wch 
bleeding might be caused by a marked 
decrease in fibrinogen. Maloney et al. 
(1949) reported the first case successfully 
treated with intravenous fibrinogen and 
blood transfusion. 
The Clotting Mechanism 
In blood clotting very many co-ordi-
nated reactions take place by which two 
recognized end-products are formed: these 
are thrombin and fibrin. Thrombin is essen-
tially an enzyme which converts fibrmo-
gen into fibrin. 
Figure I shows three distinct steps in 
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the process of coagulation. The first is the 
making of thromboplastin from the inter-
action of a platelet factor and several sub-
stances found in the plasma - thrombo-
plastinogen complex. The second step is 
the conversion of prothrombin into throm-
bin by the action of thromboplastin in the 
presence of calcium and in some way 
assisted by other plasma substances. The 
third step is the formation of fibrin by the 
action of thrombin on fibrinogen. Fibri-
nogen itself is a protein of high molecular 
weight which is synthetized in the liver; 
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Figure I shows diagrammatically the mechanism of normal clotting. 
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the normal blood fibrinogen level being 
325-400 mg. per 100 ml. It is constantly 
being converted in small amounts into 
fibrin all over the body. But this fibrin pro-
duction, is, again constantly, counteracted 
by a circulating fibrinolysin. This, coupled 
with the normal absence of thromboplas-
tins, prevents intravascular clotting. 
Mechanism of Production 
of Hypo or Afibrinogenremia 
The exact methods of production of 
coagulation defects in various hwmarrha-
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gic states are, even now, not clearly under-
stood. The placenta, decidua and to a 
lesser extent the liquor amnii, are potent 
sources of thromboplastins and in abnor-
mal conditions can liberate thromboplastin 
into the blood stream. 
Figure 2 shows that the usual mecha-
nism by which coagulation failure IS pro-
duced is probably a bi-phasic one as sug-
gested by Schneider (1951). The first phase 
is one of increased coagulability whereby 
fibrin is deposited extensively, especially 
in the pulmonary and hepatic capillary 
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Fig. 2. Diagram to show dile mechanism by which coagulation failure is produced. 
beds. Progressive defibrinogenation fol-
lows, with consequent disruption of the 
clotting mechanism,but probably the ac-
tual mechanism of fibrinogen depletion 
varies in different patients. So far good 
evidence has been produced to show that 
one of three processes can occur: 
(a) Excessive intra-uterine fibrino-
gen utilization; 
(b) Intravascular micro-coagulation 
(Beisher 1961); 
( c) Fibrinolysis and fibrinogenolysis 
(Albrechtseu et al. 1955). 
There is disagrec'ment as to which of 
these processes is the primary or most 
frequent mechanism. The argument is 
however no longer academic since potent 
therapeutic agents are now available which 
can correct or inhibit coagulation derange-
ments. 
A recent study by Willoughby (1966) 
suggests that the type of coagulation de-
fect is primarily determined by the pre-
cipitating obstetric cause. In most in-
stances it is easier to determine this than 
to distinguish between the different 
coagulation disturbances. This is impor-
tant as it helps towards simplification in 
the management. 
Clinical Conditions 
Associated with Failure 
of the Blood to Clot 
1. Concealed Accidental Hcemorrhage 
Abruptio placentce is the commonest 
underlying cause of afibrinogencemia. It 
has been shown ~hat the fibrinogen deficit 
in these cases is due to conversioCl of 
fibrinogen to fibrin locally in the retro-
placenta hcematoma. There is usually a 
striking uniform response to fibrinogen 
administration, with immediate and per-
manent correction of the circulating fibri-
nogen levels and the thrombin time. There 
is hardly ever post-partum hcemorrhage in 
these cases after giving fibrinogen. 
2. Prolonged Retention of a 
Macerated Fmtus in Utero 
The incidence of hypofibrinogememia 
in cases of intra-uterine fmtal death of 
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more than 2 weeks duration is quoted as 
1-2%. Serial fibrinogen studies often de-
monstrate a significant fibrinogen depres-
sion that is not clinically apparent. When 
the fcetus is retained for more than 5 weeks 
the incidence has been quoted to be as 
high as 25-40%. 
It is thought that in these cases the 
cause of fibrinogen deficiency is intra-
vascular micro-coagulation with no evi-
dence of fibrinogenolysis contributing to 
the coagulation defect. Experiments have 
shown that the fibrinogen level and throm-
bin time are not corrected by giving fibri-
nogen infusion when the dead fcetus is 
still in utero. 
It is of interest that the onset of this 
type of hypofibrinogencemia is of a quite 
different time-sequence from that of 
abruptio placentce, the fibrinogen falling 
slowly and steadily over a period of 5 or 
more weeks. The reason for this delayed 
onset is possibly du\~ to the more gradual 
absorption of liquor. 
When the diagnosis of intra-uterine 
death is confirmed the patient should be 
followed each week with serial fibrinogen 
estimation. Labour should be induced by 
Pitocin drip. A more recent method is that 
of intra-uterine i:r.jection of hypertonic 
saline after withdrawing 200-300 mls. of 
liquor amnii,but 2 or 3 cases of maternal 
deaths have been reported from this 
method. Artificial rupture of the mem-
branes in an effort to induce labour is con-
demned when a dead fcetus is present 
because of the risk of gas grangrene. 
3. Amniotic Fluid Embolism 
This can sometimes occur in a labour 
of sudden onset and rapid course. Labour 
in such cases may be followed by severe 
post-partum hcemorrhage due to hypo-
fibrinogencemia. It is highly probable that 
deficiency of fibrinogen is here caused 
by fibrinogenolysis due to a hyperplasmi-
ncemic state precipitated by infusion of 
amniotic fluid. The same mechanism has 
been reported in ruptured uterus and sep-
tic induced abortion. 
These cases are usually fatal since 
there is hardly any time to institute treat-
ment. Skjodt (1965) reported a success-
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fully treated case by giving 2.5 g. Epsilon 
Amino-caproic acid (E.A.C.A.) and 12 g. 
of Fibrinogen. 
4. Placenta Prcevia 
There is no obvious reason why hypo-
fibrinogenremia should not occur with 
placenta prrevia. The low incidence could 
be due to the fact that routine laboratory 
investigations of coagulation defences are 
not always requested. On the other hand, 
the free escape of blood draws attention 
to the placenta prrevia and demands ur-
gent treatment. 
5. The Use of Macromolecular Solutions 
,Solutions such as dextran may in 
themselves cause a coagulation failure. 
There is strong evidence to suggest that 
they may increase hypofibrinogenremia 
should it be present. Scott (1955) suggests 
that they act by both simple dilution of 
the already lowered fibrinogen level and 
also by encouraging precipitation of fibri-
nogen as fibrin. 
Analysis of Cases at Mulago Hospital 
Associated Obstetric Abnormality 
Accidental hremorrhage 
Placenta Prrevia 
Precipitate labour 
Retained placenta + P.P.H. 
P.P.H. 
LU.D. 
7 
1 
1 
1 
1 
Mother 
Alive 
Dead 
Parity 
Primigravida 
Gravide 1 
" 
2 
" 
3 
" 
4 
" 
5 
" 
5+ 
Unknown 
Mortality 
6 
5 
1 
1 
1 
5 
3 
Infant 
Alive 
S.B. 
N.N.D. 
Age 
14-18 
19-23 
24-28 
29-33 
34-38 
38+ 
Unknown 
Diagnosis 
4 
6 
1 
1 
3 
4 
1 
2 
This is primarily clinical and consists 
in verifying the suspicion that a clotting 
defect is present when uterine or other 
bleeding persists. In such cases it may be 
noticed that the blood is not coagulating. 
A minimal scheme of investigations 
should be performed bearing in mind that 
it case is usually one of considerable ur-
gency and may occur at times when full 
laboratory facilities are not available. A 
practical list of investigations is that sug-
gested by Willoughby (1966). (Table 1). 
Treatment 
A. Preventive 
Since severe accidental hremorrhage 
provides the greater number of cases of 
hypofibrinogenremia attention is mostly 
focused on this. 
Table I showing minimal scheme of investigation. 
Before Treatment 
Thrombin Time 
Thrombin Time 
(control) 
Fibrinogen Estimation 
Test for Active Clot 
L sis y 
Platelet Count 
Immediately after giving 
Fibrinogen 
before Obst, Abn, resolved 
Thrombin Time 
-
Fibrinogen Estimation 
Test for Active Clot 
L sis y 
Subsequently, 
before or after 
Obst. Abn, resolved 
Thrombin Time 
-
Fibrinogen Estimation 
Test for Active Clot 
L si y s 
·4 
l 
1. Early rupture of membranes -
this lowers the intra-uterine pressure, thus 
minimising the chance of absorption of 
thromboplastins into the maternal circu-
lation. 
2. Effecting delivery as soon as pos-
sible - this not only stops the absorption 
of thromboplastins but also removes the 
precipitating factor, and thus allows the 
blood fibrinogen to return to normal 
spontaneously. Pitocin should only be used 
if labour does not start within a reason-
able interval of rupturing the membranes. 
3. Induction of labour in cases of 
intra-uterine fcetal death if the fcetus is 
retained for more than 2-3 weeks or earlier 
if the fibrinogen estimation warrants it. 
4. Avoiding the use of dextran or 
other macromolecular solutions. 
B. Curative 
Early recognition of the disorder is 
important. All cases of antepartum 
hcemorrhage and intra-uterine fcetal death 
should be investigated. Treatment consists 
mainly in: 
1. Maintaining an effective blood 
volume through the administration of fresh 
blood transfusions in sufficient number to 
replace blood loss. 
2. Administration of fibrinogen only 
when it is really needed. It is expensive 
and can cause viral hepatitis. Two grams 
of fibrinogen should be administered and 
the clotting test repeated. If clotting re-
mains inadequate, another 2 grams of 
fibrinogen should be administered. In most 
cases, 4 gms. of fibrinogen should be suffi-
cent to elevate the blood fibrinogen to a 
therapeutic level. 
In cases where fibrinolysis or fibrino-
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genolysis is suspected fibrinolytic inhibi-
tors such as Epsilon-amino-caproic acid 
should be given at the same time as fibri-
nogen. Epsilon-amino-caproic acid is a 
6-amino-hexanoic acid. It is administered 
intravenously, starting with 4 gms. in the 
first half hour and then 1 gm. per hour for 
at least 12 hours. 
In cases with intra-vascular coagula-
tion the use of Heparin may be consider-
ed. This will stop intra-vascular coagula-
tion and at the same time inhibit additional 
depletion of fibrinogen. However, as most 
coagulation defects in obstetrics may be 
treated by fibrinogen alone, Heparin is 
rarely indicated. It's use is permissible in 
special cases and only when its effects 
can be monitored by special laboratory 
tests. When used, Heparin may be readily 
antagonized by Protamine Sulphate if 
bleeding is found to increase. 
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